MISSION

OcQuila Therapeutics Is positioned to be a fully integrated biopharma developing single-dose solutions to devastating eye diseases.

OcQuila combines the  know-how and transactional expertise of its founders with the speed and innovation needed to lead the modernization of medicine through gene therapy. With our ability to provide research, clinical, and manufacturing functions, we will combine partnering with commercial launch of our pipeline to provide transformative treatments to patients around the world.

Our focus is deploying innovative gene and cell therapy, as well as regenerative medicine approaches, to address rare and orphan diseases of both the front and back of the eye. 


 

LEADERSHIP

PETER NOLAN | Chairman

Peter Nolan, recently retired Chief Business Officer and Director of Oxford BioMedica, was a senior leader at the Company since it was founded in 1996. Prior to joining Oxford BioMedica, Peter served as Head of the Biotechnology Unit at the UK Department of Trade and Industry for eight years, where he was responsible for collaborative research programs between industry and the research councils. Previously he held senior positions in the Laboratory of the Government Chemist and also the Metropolitan Police Laboratory where he was a senior forensic scientist. Peter has held a number of senior posts in industry organizations, including Director of the UK BioIndustry Association and Chairman of the Oxfordshire Bioscience Network.

SARA MARY HALL |Chief Executive Officer

A scientist by training with over twenty-five years’ experience in the US, Europe, Japan, and Australia, Sara has co-founded and led four private and led a fifth, public biotech. She serves on the Board of Directors of University of Kansas Center for Technology Commercialization and is a member of the Australian Regenerative Medicine Institute (ARMI) Industry Advisory Committee. A member of the Kansas chapter of the International Women’s Forum, Sara has been involved in national and international initiatives for women and girls in the sciences, and is a professional violinist performing with the Bainbridge Symphony Orchestra and Bridges: A String Ensemble. The winner of two R&D 100 awards for scientific innovation while still at the bench, Sara is a creative, experienced, and driven executive with a specialty in and passion for first-in-class products and concepts.

SARA MARY HALL |Chief Executive Officer

A scientist by training with over twenty-five years’ experience in the US, Europe, Japan, and Australia, Sara has co-founded and led four private and led a fifth, public biotech. She serves on the Board of Directors of University of Kansas Center for Technology Commercialization and is a member of the Australian Regenerative Medicine Institute (ARMI) Industry Advisory Committee. A member of the Kansas chapter of the International Women’s Forum, Sara has been involved in national and international initiatives for women and girls in the sciences, and is a professional violinist performing with the Bainbridge Symphony Orchestra and Bridges: A String Ensemble. The winner of two R&D 100 awards for scientific innovation while still at the bench, Sara is a creative, experienced, and driven executive with a specialty in and passion for first-in-class products and concepts.

CURTIS SCRIBNER, MD, MBA | Consulting Chief Medical Officer

 Dr. Scribner is an independent regulatory consultant in the San Francisco Bay Area and a board-certified physician in internal medicine with direct experience in developing and running small and large clinical and regulatory programs, especially in the area of gene therapy and for ophthalmology programs. Over the last 5 years, he has led meetings with essentially every Division in CDER and CBER for his clients in a broad array of clinical areas, from pre-IND through pre-NDA discussions. He has held senior positions at RRD International, Intarcia Therapeutics, where he was the Vice President of Regulatory and Quality Affairs, and for Quintiles Consulting as the Chief Regulatory Consultant. Prior to Quintiles Consulting, Dr. Scribner spent 10 years at FDA, where he held a variety of positions and was involved in
reviewing products regulated by the Center for Biologics Evaluation and Research and as Deputy Director of the Office of Blood Research and Review. Dr. Scribner holds an MD from the University of Colorado College of Medicine, an MBA from the University of Maryland College of Business and Management, and a BA in biology from Grinnell College.

JILL MARTIN |Consulting Chief Intellectual Property Officer

Jill Martin, a registered patent agent with the U.S. Patent & Trademark Office, has over twenty-five years in the life sciences sector transitioning from lab bench to patent office to management team member as Vice President of Intellectual Property for BioMedica, Inc. – a wholly owned subsidiary of Oxford BioMedica – to patent portfolio consultancy with emerging companies helping to leverage global IP assets for corporate development.  Prior to her time at BioMedica, Jill spent five years as a patent examiner of the gene therapy arts at the U.S. Patent & Trademark Office.  Jill is passionate about supporting the mission that every child in her community has access to STEM-based learning opportunities and served from 2015-2017 as a board member of the non-profit organization, the Solana Beach Schools Foundation.  An enthusiast of “bluemind” therapy, the intersection of wild water and the human brain, Jill enjoys catching a wave or two at her local surf breaks.

JILL MARTIN |Consulting Chief Intellectual Property Officer

Jill Martin, a registered patent agent with the U.S. Patent & Trademark Office, has over twenty-five years in the life sciences sector transitioning from lab bench to patent office to management team member as Vice President of Intellectual Property for BioMedica, Inc. – a wholly owned subsidiary of Oxford BioMedica – to patent portfolio consultancy with emerging companies helping to leverage global IP assets for corporate development.  Prior to her time at BioMedica, Jill spent five years as a patent examiner of the gene therapy arts at the U.S. Patent & Trademark Office.  Jill is passionate about supporting the mission that every child in her community has access to STEM-based learning opportunities and served from 2015-2017 as a board member of the non-profit organization, the Solana Beach Schools Foundation.  An enthusiast of “bluemind” therapy, the intersection of wild water and the human brain, Jill enjoys catching a wave or two at her local surf breaks.

 

Find out more

15 + 11 =